| Overview |
| bs-13235R-PE |
| FXYD7 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Rat, Cow, Sheep |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FXYD7 |
| 21-60/80 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 53822 |
| Cell membrane |
| FLJ25096; FXYD domain containing ion transport regulator 7; FXYD domain-containing ion transport regulator 7; Fxyd7; FXYD7_HUMAN. |
| This reference sequence was derived from multiple replicate ESTs and validated by similar human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. This gene product, FXYD7, is novel and has not been characterized as a protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu., Dec 2000]. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz